Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans.
Endocannabinoids
Laparoscopic sleeve gastrectomy
Metabolic parameters
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
24
9
2018
medline:
1
1
2020
entrez:
24
9
2018
Statut:
ppublish
Résumé
The endocannabinoid (eCB) system plays a key role in the development of obesity and its comorbidities. Limited information exists on the changes in circulating eCBs following bariatric surgery. This study aims to (i) assess the circulating levels of eCBs and related molecules and (ii) examine the association between their levels and numerous clinical/metabolic features pre- and post-operatively. Sixty-five morbidly obese patients (age 42.78 ± 9.27 years; BMI 42.00 ± 5.01 kg/m Levels of 2-AG, AEA, and AA were reduced post operatively with no differences in serum OEA levels. The delta changes in eCB levels between pre- and post-operation were correlated with the delta of different metabolic parameters. Positive correlations were found between delta AA and waist circumference (WC) (r = 0.28, P < 0.05), free fat mass (r = 0.26, P < 0.05), SteatoTest score (r = 0.45, P < 0.05), and ALT (r = 0.32, P < 0.05). Delta AEA levels positively correlated with WC (r = 0.30, P < 0.05). Delta 2-AG levels positively correlated with total cholesterol (r = 0.27, P < 0.05), triglycerides (r = 0.55, P < 0.05), and SteatoTest score (r = 0.27, P < 0.05). Delta OEA levels negatively correlated with fasting glucose levels (r = - 0.27, P < 0.05). This study provides compelling evidence that LSG surgery induces reductions in the circulating 2-AG, AEA, and AA levels, and that these changes are associated with clinical benefits related to the surgery including reduced fat mass, hepatic steatosis, glucose, and improved lipid profile.
Sections du résumé
BACKGROUND
The endocannabinoid (eCB) system plays a key role in the development of obesity and its comorbidities. Limited information exists on the changes in circulating eCBs following bariatric surgery.
OBJECTIVES
This study aims to (i) assess the circulating levels of eCBs and related molecules and (ii) examine the association between their levels and numerous clinical/metabolic features pre- and post-operatively.
METHODS
Sixty-five morbidly obese patients (age 42.78 ± 9.27 years; BMI 42.00 ± 5.01 kg/m
RESULTS
Levels of 2-AG, AEA, and AA were reduced post operatively with no differences in serum OEA levels. The delta changes in eCB levels between pre- and post-operation were correlated with the delta of different metabolic parameters. Positive correlations were found between delta AA and waist circumference (WC) (r = 0.28, P < 0.05), free fat mass (r = 0.26, P < 0.05), SteatoTest score (r = 0.45, P < 0.05), and ALT (r = 0.32, P < 0.05). Delta AEA levels positively correlated with WC (r = 0.30, P < 0.05). Delta 2-AG levels positively correlated with total cholesterol (r = 0.27, P < 0.05), triglycerides (r = 0.55, P < 0.05), and SteatoTest score (r = 0.27, P < 0.05). Delta OEA levels negatively correlated with fasting glucose levels (r = - 0.27, P < 0.05).
CONCLUSIONS
This study provides compelling evidence that LSG surgery induces reductions in the circulating 2-AG, AEA, and AA levels, and that these changes are associated with clinical benefits related to the surgery including reduced fat mass, hepatic steatosis, glucose, and improved lipid profile.
Identifiants
pubmed: 30244333
doi: 10.1007/s11695-018-3517-0
pii: 10.1007/s11695-018-3517-0
doi:
Substances chimiques
Biomarkers
0
Endocannabinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-276Références
J Diabetes Res. 2015;2015:680867
pubmed: 25874237
Gastroenterology. 2010 Dec;139(6):1961-1971.e1
pubmed: 20600015
Cell Metab. 2010 Apr 7;11(4):273-85
pubmed: 20374960
J Clin Invest. 2008 Sep;118(9):3160-9
pubmed: 18677409
PLoS One. 2012;7(7):e42399
pubmed: 22860123
Diabetologia. 2009 Feb;52(2):213-7
pubmed: 18972095
Curr Opin Gastroenterol. 2017 Sep;33(5):358-365
pubmed: 28682794
Thromb Haemost. 2015 Apr;113(4):838-50
pubmed: 25413674
Obesity (Silver Spring). 2017 Jan;25(1):94-101
pubmed: 27863097
Obesity (Silver Spring). 2014 Jan;22(1):211-6
pubmed: 23616305
Int J Obes (Lond). 2007 Apr;31(4):692-9
pubmed: 17224929
N Engl J Med. 2017 Jul 6;377(1):80-81
pubmed: 28604226
Eur J Gastroenterol Hepatol. 2018 May;30(5):569-577
pubmed: 29406435
Mol Pharmacol. 2003 Apr;63(4):908-14
pubmed: 12644592
Int J Obes (Lond). 2018 Feb;42(2):147-155
pubmed: 28852205
J Am Soc Nephrol. 2017 Dec;28(12):3518-3532
pubmed: 28860163
Ann Surg. 2008 May;247(5):779-90
pubmed: 18438115
Neuropsychopharmacology. 2018 Jan;43(1):155-172
pubmed: 28653665
Diabetes. 2010 Apr;59(4):926-34
pubmed: 20110567
Eur J Intern Med. 2018 Mar;49:23-29
pubmed: 29336868
PLoS One. 2010 Jan 20;5(1):e8792
pubmed: 20098695
PLoS One. 2012;7(3):e30325
pubmed: 22431959
Trends Endocrinol Metab. 2015 Oct;26(10):524-537
pubmed: 26412154
Diabetes. 2006 Nov;55(11):3053-60
pubmed: 17065342
N Engl J Med. 2017 Jan 19;376(3):254-266
pubmed: 28099824
Obes Surg. 2017 Sep;27(9):2279-2289
pubmed: 28405878
Cell Metab. 2013 Apr 2;17(4):475-90
pubmed: 23562074
Gastroenterol Res Pract. 2013;2013:256145
pubmed: 24348530
Eur Heart J. 2013 Jul;34(27):2063-73
pubmed: 23487518
Diabetes. 2005 Oct;54(10):2838-43
pubmed: 16186383
Cardiovasc Diabetol. 2012 Feb 22;11:16
pubmed: 22356810